External gel used for treating diabetic foot, and preparation method and application thereof

Abstract

The invention relates to an external gel used for treating diabetic foot, and a preparation method and an application thereof. Specifically, the invention relates to an external gel preparation with oxygen-carrying and antibacterial materials, and containing recombinant human epidermal growth factor (rhEGF). The preparation basically comprises: a medicine component recombinant human epidermal growth factor (rhEGF), an oxygen-carrying material, an antibacterial material, a gel substrate, a stabilizing agent, a humectant, a penetration enhancing agent, a surfactant, and a pH regulation agent.

Description

technical field [0001] The invention relates to an external gel preparation for treating diabetic foot, in particular to an external preparation for treating diabetic foot which has oxygen-carrying and antibacterial materials and contains recombinant human epidermal growth factor (rhEGF). Background technique [0002] Diabetes is one of the most common diseases in the world. According to a report by the World Health Organization, diabetes has become the fourth leading cause of death. By 2025, the number of diabetic patients in the world will reach 300 million. 10% to 15% of diabetic patients suffer from foot complications, so diabetic foot is one of the main chronic complications of diabetes. Its pathogenesis involves peripheral neuropathy, vasculopathy, and infection. The most common clinical manifestation is skin ulcer of the lower extremities, and severe cases may be amputated due to gangrene of the lower extremities, or even die. The basic characteristics of diabetic f...

AI Technical Summary

Problems solved by technology

Chinese patent CN101053657A, an external preparation for treating refractory skin ulcers, which contains epidermal growth factor, antibacterial drugs and insulin, which can promote skin healing and inhibit bacterial growth, but there is no oxygen-carrying material to increase the oxygen content of the wound

2) The application of oxygen-carrying materials has been mentioned in the existing patents, the world patent WO / 2010 / 065059, PERFLUOROCARBON GEL FORMULATIONS, which uses perfluorocarbons to increase the oxygen content of skin tissue, but this patent is mainly used in cosmetics, No antibacterial and tissue growth-promoting effects

3) The active ingredient of the drug Regranex, which has been marketed in the United States, is human recombinant platelet-derived growth factor. This product has obvious curative effect on the treatment of diabetic foot, but clinical observations show that the cancer rate increases after the drug is used, so the FDA proposes to use it when the benefits outweigh the risks.

Although the above-mentioned patents and medicines relate to the treatment method of diabetic foot, they all have certain limitations and lack the composition of the best medicine (drug and material) for diabetic foot